Inclusion Criteria:

          -  Patients with AML and the presence of FLT3 mutation

          -  Patients with secondary AML or therapy related disease (t-AML) are eligible

          -  If the patient has co-morbid medical illness, life expectancy attributed to this must
             be greater than 6 months

          -  Eastern Cooperative Oncology Group (ECOG) performance status =< 2

          -  Total bilirubin < 2.0mg/dL unless due to Gilbert's disease

          -  Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase
             [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT])
             < 2.5 X institutional upper limit of normal

          -  Creatinine (Cr) clearance > 50 mL/min by Cockcroft-Gault calculation

          -  New York Heart Association (NYHA) congestive heart failure (CHF) class II or better

          -  Cardiac ejection fraction >= 50% for Arm A, >= 40% for Arm B

          -  Female patients of child-bearing potential must agree to use dual methods of
             contraception and have a negative serum pregnancy test at screening, and male patients
             must use an effective barrier method of contraception if sexually active with a female
             of child-bearing potential; acceptable methods of contraception are condoms with
             contraceptive foam, oral, implantable or injectable contraceptives, contraceptive
             patch, intrauterine device, diaphragm with spermicidal gel, or a sexual partner who is
             surgically sterilized or post-menopausal; for both male and female patients, effective
             methods of contraception must be used throughout the study and for three months
             following the last dose

          -  Ability to understand and willingness to sign the written informed consent document

          -  Human immunodeficiency virus (HIV) infection without history of acquired immune
             deficiency syndrome (AIDS) and sufficiently high cluster of differentiation (CD)4
             cells (> 400/mm^3) and low HIV viral loads (< 30,000 copies/ml plasma) not requiring
             anti-HIV therapy are eligible

        Exclusion Criteria:

          -  Patients with core-binding factor AML (inv[16], t[8;21]) or t(15;17)

          -  Patients who have had chemotherapy or radiotherapy within 2 weeks (6 weeks for
             nitrosoureas or mitomycin C) prior to entering the study; treatment with hydroxyurea
             is permitted during cycle 1 to maintain white blood cell (WBC) < 40,000/uL

          -  Patients receiving any other investigational agents or patients that have received
             other investigational agents within 14 days of enrollment

          -  Patients with active central nervous system (CNS) malignancy

          -  Major surgery within 2 weeks before day 1

          -  Uncontrolled active infection; patients with infection requiring parenteral
             antibiotics are eligible if the infection is controlled

          -  Patients with significantly diseased or obstructed gastrointestinal tract

          -  Uncontrolled intercurrent illness including, but not limited to, symptomatic
             congestive heart failure (New York Heart Association [NYHA] class III or IV), unstable
             angina pectoris, myocardial infarction within 6 months prior to enrollment, severe
             uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute
             ischemia or active conduction system abnormalities; prior to study entry, any
             electrocardiogram (ECG) abnormality at screening has to be documented by the
             investigator as not medically relevant

          -  Patients with serious medical or psychiatric illness likely to interfere with
             participation in this clinical study

          -  Pregnant women or women who are breastfeeding are excluded from this study;
             confirmation that the subject is not pregnant must be established by a negative serum
             beta-human chorionic gonadotropin (beta-hCG) pregnancy test result obtained during
             screening; pregnancy testing is not required for post-menopausal or surgically
             sterilized women

          -  Patients with advanced malignant solid tumors

          -  Patients who are not able to swallow capsules or tablets

          -  Patients with baseline corrected QT (QTc) > 500 ms